TAAR1 and psychotic disorder: In addition to inhibiting dopamine release, selective TAAR1 agonists (RO5256390, RO5263397) attenuate cocaine-induced locomotor activity, as well as activity induced by N-methyl-D-aspartate receptor agonists, suggesting that the TAAR1 influences endocrine [14] and neuropsychiatric disorders including depression, schizophrenia, and psychosis [10, 15–19].